Coherus Oncology, Inc. CHRS
Coherus Oncology, Inc. (Nasdaq: CHRS) is an oncology drug developer. Its lead program, LOQTORZI (toripalimab-tpzi), is in Phase 2 for Nasopharyngeal carcinoma (1L with cisplatin/gemcitabine; monotherapy after platinum). Its next catalyst on record is tagmokitug: Initiation of Phase 1b study with pasritamig (Janssen) in metastatic castration-resistant prostate cancer (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tagmokitug — Initiation of Phase 1b study with pasritamig (Janssen) in metastatic castration-resistant prostate cancer (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LOQTORZI (toripalimab-tpzi), anti-PD-1 | Nasopharyngeal carcinoma (FDA approved Oct 2023; US launch Jan 2024) | antibody | Approved |
| casdozokitug (CHS-388), anti-IL-27 | 1L hepatocellular carcinoma, with toripalimab and bevacizumab | antibody | Phase 2 |
| tagmokitug (CHS-114), anti-CCR8 | HNSCC, upper GI adenocarcinoma, ESCC, colorectal cancer (Phase 1b/2a) | antibody | Phase 1 |
Recent results and decisions
- Aug 28, 2026n/a Coherus Oncology entered into an at-the-market sales agreement for up to $50 million in common stock sales.
The Company may offer and sell, from time to time, through or to the Agent, acting as agent or principal, shares of the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $50.0 million.
Filing - May 11, 2026completed enrollment Enrollment completed in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC.
Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected in mid-2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.